FINWIRES · TerminalLIVE
FINWIRES

欧洲、中东和非洲地区石油市场最新动态:由于外交僵局,原油价格徘徊在三周高位附近

By

-- 周二,原油期货价格飙升至逾三周高位,市场对伊朗提出的新和平方案仍持怀疑态度。 近月穆尔班原油期货上涨2.5%,至每桶106.84美元;布伦特原油期货上涨2.7%,至每桶111.16美元。 尽管有报道称,德黑兰提出以重新开放霍尔木兹海峡为条件,换取美国解除海上封锁,但德国商业银行的分析师指出,在经历了多次虚假消息后,市场对这类说法“正在失去信心”。 盛宝银行的分析师表示:“美伊和平谈判仍处于僵局,重启谈判的努力陷入停滞。据报道,伊朗周末向美国提出了重新开放霍尔木兹海峡的方案,白宫证实,特朗普总统的国家安全团队正在讨论该方案。” 然而,阿联酋周二宣布退出欧佩克和欧佩克+,这对全球石油卡特尔来说无疑是一记重击。 与此同时,美国主导的封锁带来的实际影响日益显著。 Kpler的数据显示,伊朗石油出口量暴跌70%,从3月份的日均185万桶骤降至仅56.7万桶。 据估计,伊朗的储油设施剩余容量不足22天,这意味着到5月中旬,该国将面临高达150万桶/日的强制减产。 周一,两艘与伊朗有关联的超级油轮“蒂法尼”号和“菲尼克斯”号在斯里兰卡附近被美军拦截后,转向东行,远离封锁线,这更加凸显了供应缺口。 加拿大皇家银行资本市场的策略师指出,展望未来,全球消费者面临“残酷夏季”的可能性越来越大。 RBC分析师警告称,这场已持续三个月的冲突引发了现代史上最大的供应冲击,导致近10亿桶原油和成品油供应中断。 即便外交上取得突破,专家也警告说,基础设施和物流的破坏将使中东地区的石油生产复苏极其缓慢,从而确保高油价和库存紧张的局面在旺季需求高峰期持续存在。

Related Articles

Sectors

Sector Update: Tech Stocks Fall Late Afternoon

Tech stocks fell late Tuesday afternoon, with the State Street Technology Select Sector SPDR ETF (XLK) dropping 1.5% and the State Street SPDR S&P Semiconductor ETF (XSD) slumping 4.4%.The Philadelphia Semiconductor index shed 3.3%.In corporate news, OpenAI recently missed its own targets for new users and revenue, the Wall Street Journal reported late Monday, citing people familiar with the matter. Tech bellwether Nvidia (NVDA) fell 1.2%, Broadcom (AVGO) dropped 4.2%, Advanced Micro Devices (AMD) shed 3.1%, Oracle (ORCL) lost 3.6%, and Intel (INTC) declined 1.4%.Lam Research (LRCX), Applied Materials (AMAT) and KLA (KLAC) were among the chip equipment companies believed to have received a letter last week from the US Department of Commerce ordering them to halt certain tool shipments to China's second-largest chipmaker Hua Hong, Reuters reported. Lam declined 3%, Applied Materials dropped 5.1%, and KLA shed 4.1%.Amazon.com (AMZN) plans to make OpenAI's artificial intelligence models available to its customers after Microsoft (MSFT) relinquished its exclusive rights to resell the ChatGPT maker's products, Bloomberg reported Tuesday, citing Amazon Web Services CEO Matt Garman in a Bloomberg Television interview. Amazon shares were down 0.6%, and Microsoft rose 0.6%.Spotify Technology (SPOT) reported stronger-than-expected Q1 profit, but its premium subscriber growth and outlook disappointed investors. The stock fell 12%.

$AMAT$AMD$AMZN$AVGO$INTC$KLAC$LRCX$MSFT$NVDA$ORCL$SPOT
Research

Research Alert: Paccar: Q1 Eps Match Expectations; Class-8 Outlook Reiterated

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PCAR's Q1 results matched consensus with operating EPS of $1.15 vs. $0.96 in the prior year, supported by the absence of litigation charges that impacted Q1 2025. New truck deliveries fell 7K units to 33.1K globally, with North American Class-8 shipments declining while Europe showed strength. The Parts business managed positive expansion despite truck sales softness, benefiting from strategic investments in distribution infrastructure. Management maintained an upbeat tone on customer demand trends, though their North American outlook for retail Class-8 truck sales remained unchanged from Q4. PCAR generated healthy operating cash flow of $972M vs. $910M and maintained a strong balance sheet, in our view. Management projected full-year capex of ~$750M and R&D expenses of ~$475M for next-generation powertrains. We see the unchanged shipment projections as a signal that management is not entirely confident an inflection is occurring stronger than previously anticipated.

$PCAR
Australia

Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data

Erasca (ERAS) shares fell 48% Tuesday after the company reported preliminary phase 1 dose-escalation data for its experimental ERAS-0015 in patients with RAS-mutant solid tumors, including colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma.The preliminary data, from ongoing trials in the US and China, suggest ERAS-0015 may be combined with standard-of-care doses of panitumumab, positioning it as a potential backbone therapy for future combination regimens, the company said.The therapy was generally "well tolerated," with no dose-limiting toxicities or treatment discontinuations due to adverse events, according to a statement.Erasca said it selected 24 mg and 32 mg once daily as recommended doses for further study and said the drug showed "promising clinical potential" for combination use with panitumumab.In a regulatory filing, the company said a patient, who was a 66 year-old male with heavily pretreated metastatic pancreatic adenocarcinoma, had died. The company said grade 3 treatment-related adverse events of pneumonitis progressed to grade 5 following withdrawal of supportive care per patient decision.Price: $9.96, Change: $-9.20, Percent Change: -48.02%

$ERAS